Search

everythinglearnresearchcommunity

for

Search:↓

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Mogamulizumab can cause hair loss and skin rashes.

A3B5 can reduce skin pigmentation and slow melanoma growth.

Selumetinib causes fewer and less severe skin issues in children than binimetinib.

The treatment showed high response rates and was well-tolerated, potentially extending patient survival.

The document concludes that managing side effects of MS therapies is crucial for treatment success and patient adherence.

Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.

IMG-007 helps regrow hair and reduce scalp inflammation in severe alopecia areata.

Ipilimumab can cause various adverse events in elderly patients, especially affecting the gastrointestinal and endocrine systems.

Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.

Guselkumab effectively treats skin reactions caused by adalimumab in certain conditions.

Gemcitabine and paclitaxel are effective and safe as first-line treatment for metastatic breast cancer.

Using an anti-ICAM-1 antibody with rapamycin improves hair transplant survival in monkeys.

SARMs may be an effective treatment for a certain type of breast cancer by blocking cancer growth and spread.

Alopecia universalis from alemtuzumab in multiple sclerosis can be reversed with specific treatments.

Bimekizumab effectively treated a man's chronic beard hair loss.

MT-DADMe-ImmA can selectively kill head and neck cancer cells without harming normal cells.

Adalimumab significantly improved symptoms and quality of life in two patients with Hidradenitis Suppurativa.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

The choice between belimumab and anifrolumab depends on the specific symptoms of the patient's lupus.

BMS-470539 reduces skin fibrosis and inflammation.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Intralesional methotrexate effectively treats patchy alopecia areata by reducing inflammation.

Azathioprine can help with relapses and disability in NMOSD but has more side effects and needs more research.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.

Mefloquine, an antimalarial drug, is effective in killing melanoma cells resistant to other treatments by causing lethal stress in the cells.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

Targeting METTL1 may help slow papillary thyroid cancer growth and spread.

Nano-Pulse Stimulation™ Therapy is more effective and less damaging than cryoablation for treating melanoma tumors in mice.